Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01466361 · ClinicalTrials.gov registry record · Phase 2

Evaluation of the Nicotine Lozenge in Relief of Provoked Acute Craving

A Phase 2 study, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 2
Development phase
187
Enrollment target

NCT01466361 is a Phase 2 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 187 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01466361, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 2
Development phase
187 participants
Enrollment target

Study Summary

This study is designed to evaluate the ability of a nicotine lozenge to relieve craving for a cigarette compared to a matched placebo (a placebo is like sugar pill and contains no active).

Interventions

  • DRUG Placebo
  • DRUG Nicotine lower dose
  • DRUG Nicotine higher dose

Trial Details

FieldValue
Enrollment Target 187 participants
Start Date 2010-09
Est. Completion 2010-12
Phase Phase 2

Sponsor

GlaxoSmithKline

1,345 total trials

What the Registry Record Tells You About NCT01466361

The ClinicalTrials.gov registry entry for NCT01466361 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 187 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT01466361 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01466361 about?

NCT01466361 is a clinical study titled "Evaluation of the Nicotine Lozenge in Relief of Provoked Acute Craving". This study is designed to evaluate the ability of a nicotine lozenge to relieve craving for a cigarette compared to a matched placebo (a placebo is like sugar pill and contains no active).

What is the current status of trial NCT01466361?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 187 participants. The study started on 2010-09. Estimated completion is 2010-12.

What interventions are being tested in trial NCT01466361?

The interventions under investigation include: Placebo (DRUG), Nicotine lower dose (DRUG), Nicotine higher dose (DRUG).

Who is sponsoring clinical trial NCT01466361?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.